GlassScriptPhysician profile
Umesh K Sabharwal
NPI 1831192160
$13,478.11
in general payments reported to CMS, 2019-2025
36 companies · $1,598 in 2025
The $1,598 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,721 · 2020: $877 · 2021: $1,545 · 2022: $2,101 · 2023: $1,463 · 2024: $1,172 · 2025: $1,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,029 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,029.12 |
| Education | $204.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,807.47 | 2019-2025 | Otezla, Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $1,579.40 | 2019-2025 | Nucala, Benlysta, Arexvy |
| Abbvie INC. | $1,140.18 | 2019-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,069.24 | 2019-2025 | |
| Janssen Biotech, INC. | $1,040.11 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Janssen Scientific Affairs, LLC | $898.36 | 2019-2024 | Tremfya |
| Genzyme Corporation | $644.47 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $518.72 | 2019-2025 | Tezspire |
| Pfizer INC. | $479.85 | 2019-2023 | |
| Ucb, INC. | $477.38 | 2019-2025 | Bimzelx |
| Optinose US, INC. | $417.57 | 2019-2022 | |
| Lilly USA, LLC | $393.89 | 2019-2023 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.49 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $311.94 | 2022-2023 | Lupkynis |
| Radius Health, INC. | $294.44 | 2019-2025 | Tymlos |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $292.81 | 2025 | Dawnzera |
| Regeneron Healthcare Solutions, INC. | $266.38 | 2019-2023 | Dupixent |
| Horizon Therapeutics Plc | $187.45 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $186.47 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $173.17 | 2019 | |
| Genentech USA, INC. | $167.51 | 2019-2025 | Xolair |
| Celgene Corporation | $136.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $118.26 | 2019-2025 | Orencia |
| Sanofi-Aventis U.S. LLC | $92.78 | 2019 | |
| Octapharma USA, INC. | $74.38 | 2023-2025 | Cutaquig |
| Xeris Pharmaceuticals, INC. | $55.67 | 2025 | Recorlev, Gvoke Hypopen |
| Madrigal Pharmaceuticals | $47.04 | 2025 | Rezdiffra |
| Csl Behring | $42.50 | 2019 | |
| Inspire Medical Systems, INC. | $40.77 | 2025 | Inspire |
| Pacira Therapeutics, INC. | $32.92 | 2019 | |
| Alfasigma USA, INC. | $24.71 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.58 | 2022 | |
| Fresenius Kabi USA, LLC | $23.15 | 2023 | Idacio |
| Grifols USA, LLC | $20.83 | 2023 | Xembify |
| Mallinckrodt Hospital Products INC. | $19.95 | 2020 | |
| Novo Nordisk INC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umesh Sabharwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.